Haloperidol Injection

Generic name: Pronounced as (ha loe per' i dole)
Brand names
  • Haldol®
  • Haldol® Decanoate
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2017

Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as haloperidol have an increased chance of death during treatment.

Haloperidol injection and haloperidol extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with haloperidol injection or haloperidol extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs

Talk to your doctor about the risk(s) of receiving haloperidol injection or haloperidol extended-release injection.

Haloperidol injection and haloperidol extended-release injection are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Haloperidol injection is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal tics (uncontrollable need to repeat sounds or words) in people who have Tourette's disorder (condition characterized by motor or verbal tics). Haloperidol is in a class of medications called conventional antipsychotics. It works by decreasing abnormal excitement in the brain.

Haloperidol injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol injection is usually given as needed for agitation, motor tics, or verbal tics. If you still have symptoms after you receive your first dose, you may be given one or more additional doses. Haloperidol extended-release injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol extended-release injection is usually given once every 4 weeks.

Haloperidol injection and haloperidol extended-release injection may help control your symptoms but will not cure your condition. Continue to keep appointments to receive haloperidol even if you feel well. Talk to your doctor if you do not feel like you are getting better during your treatment with haloperidol injection.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving haloperidol injection or haloperidol extended-release injection,

  • tell your doctor and pharmacist if you are allergic to haloperidol, any other medications, or any of the ingredients in haloperidol injection or haloperidol extended-release injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); amiodarone (Cordarone, Nexterone, Pacerone); anticoagulants (blood thinners); antifungals medications such as itraconazole (Onmel, Sporanox) and ketoconazole (Nizoral); antihistamines (in cough and cold medications); medications for anxiety, depression, irritable bowel disease, mental illness, motion sickness, Parkinson's disease, seizures, ulcers, or urinary problems; buspirone; carbamazepine (Carbatrol, Tegretol, Teril, others); chlorpromazine; disopyramide (Norpace); diuretics ('water pills'); epinephrine (Adrenalin, Epipen, Twinject, others); erythromycin (E.E.S., E-Mycin, Erythrocin); fluoxetine (Prozac, Sarafem, Selfemra); fluvoxamine (Luvox); lithium (Lithobid); moxifloxacin (Avelox); narcotic medications for pain; nefazodone; paroxetine (Brisdelle, Paxil, Pexeva); promethazine (Promethegan); quinidine (in Nuedexta); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); sedatives; sertraline (Zoloft); sleeping pills; tranquilizers; and venlafaxine (Effexor XR). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with haloperidol, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • tell your doctor if you have Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Your doctor will probably tell you not to receive haloperidol injection.

  • tell your doctor if you have a low number of white blood cells. Also tell your doctor if you have or have ever had QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death); bipolar disorder (condition that causes episodes of depression, episodes of mania, and other abnormal moods); trouble keeping your balance; an abnormal electroencephalogram (EEG; a test that records electrical activity in the brain); seizures; an irregular heartbeat; low levels of potassium or magnesium in your blood; or heart or thyroid disease.

  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while receiving haloperidol, call your doctor. Haloperidol may cause problems in newborns following delivery if it is given during the last months of pregnancy.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving haloperidol injection.

  • you should know that receiving haloperidol injection or haloperidol extended-release injection may make you drowsy and may affect your ability to think clearly, make decisions, and react quickly. Do not drive a car or operate machinery after you receive haloperidol injection or haloperidol extended-release injection until you know how this medication affects you.

  • you should know that alcohol can add to the drowsiness caused by this medication. Do not drink alcohol during your treatment with haloperidol.

  • you should know that haloperidol injection may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

Unless your doctor tells you otherwise, continue your normal diet.

If you forget to keep an appointment to receive haloperidol extended-release injection, call your doctor to schedule another appointment as soon as possible.

  • Haloperidol injection or haloperidol extended-release injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • mood changes

    • difficulty falling asleep or staying asleep

    • restlessness

    • anxiety

    • agitation

    • dizziness, feeling unsteady, or having trouble keeping your balance

    • headache

    • dry mouth

    • increased saliva

    • blurred vision

    • loss of appetite

    • constipation

    • diarrhea

    • heartburn

    • nausea

    • vomiting

    • breast enlargement or pain

    • breast milk production

    • missed menstrual periods

    • decreased sexual ability in men

    • increased sexual desire

    • difficulty urinating

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

    • fever

    • muscle stiffness

    • falling

    • confusion

    • fast or irregular heartbeat

    • sweating

    • decreased thirst

    • involuntary movements of tongue, face, mouth or jaw

    • uncontrollable eye movements

    • unusual, slowed, or uncontrollable movements of any part of the body

    • tightness in the throat

    • fine, worm-like tongue movements

    • neck cramps

    • difficulty breathing or swallowing

    • tongue that sticks out of the mouth

    • uncontrollable, rhythmic face, mouth, or jaw movements

    • difficulty walking

    • difficulty talking

    • seizures

    • seeing things or hearing voices that do not exist

    • yellowing of the skin or eyes

    • erection that lasts for hours

  • Haloperidol injection or haloperidol extended-release injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • unusual, slowed, or uncontrollable movements of any part of the body

  • uncontrollable shaking of a part of the body

  • stiff or weak muscles

  • sedation

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to haloperidol injection or haloperidol extended-release injection.

Ask your pharmacist any questions you have about haloperidol injection or haloperidol extended-release injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.
Repaglinide Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Haloperidol.
Montelukast Montelukast The serum concentration of Haloperidol can be increased when it is combined with Montelukast.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Haloperidol.
Leflunomide Leflunomide The serum concentration of Haloperidol can be decreased when it is combined with Leflunomide.
Delavirdine Delavirdine The serum concentration of Haloperidol can be increased when it is combined with Delavirdine.
Nevirapine Nevirapine The serum concentration of Haloperidol can be increased when it is combined with Nevirapine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Haloperidol.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dolasetron.
Aminophylline Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Haloperidol.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Anagrelide.
Candesartan Candesartan The metabolism of Haloperidol can be decreased when combined with Candesartan.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Haloperidol.
Clopidogrel Clopidogrel The serum concentration of Haloperidol can be increased when it is combined with Clopidogrel.
Diphenoxylate Diphenoxylate The risk or severity of CNS depression can be increased when Haloperidol is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Haloperidol.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The serum concentration of Haloperidol can be increased when it is combined with Conjugated estrogens.
Fenofibrate Fenofibrate The serum concentration of Haloperidol can be increased when it is combined with Fenofibrate.
Guanfacine Guanfacine The risk or severity of CNS depression can be increased when Haloperidol is combined with Guanfacine.
Magnesium Hydroxide Magnesium Hydroxide Haloperidol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine Methylergonovine The serum concentration of Haloperidol can be increased when it is combined with Methylergometrine.
Miglitol Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Haloperidol.
Mycophenolate Mycophenolate Haloperidol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of CNS depression can be increased when Naratriptan is combined with Haloperidol.
Olsalazine Olsalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Olsalazine.
Paregoric Paregoric The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of CNS depression can be increased when Haloperidol is combined with Pentazocine.
Potassium Potassium Potassium may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The serum concentration of Haloperidol can be increased when it is combined with Prednisone.
Ranitidine Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Haloperidol.
Reserpine Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Haloperidol.
Rizatriptan Rizatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Sumatriptan.
Tacrolimus Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tizanidine.
Triamcinolone Triamcinolone The serum concentration of Haloperidol can be increased when it is combined with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Haloperidol.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection The serum concentration of Haloperidol can be increased when it is combined with Doxycycline.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Haloperidol.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol.
Hydromorphone Injection Hydromorphone Injection The risk or severity of CNS depression can be increased when Hydromorphone is combined with Haloperidol.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol.
Meperidine Injection Meperidine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Meperidine.
Methylprednisolone Injection Methylprednisolone Injection The serum concentration of Haloperidol can be increased when it is combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Haloperidol.
Morphine Injection Morphine Injection The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Haloperidol may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Zidovudine Injection Zidovudine Injection The serum concentration of Haloperidol can be increased when it is combined with Zidovudine.
Altretamine Altretamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cyclosporine Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Granisetron.
Torsemide Torsemide The metabolism of Haloperidol can be decreased when combined with Torasemide.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Haloperidol.
Alosetron Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Haloperidol.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dofetilide.
Entacapone Entacapone The risk or severity of CNS depression can be increased when Entacapone is combined with Haloperidol.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Haloperidol.
Meloxicam Meloxicam The serum concentration of Haloperidol can be increased when it is combined with Meloxicam.
Oxcarbazepine Oxcarbazepine The risk or severity of CNS depression can be increased when Oxcarbazepine is combined with Haloperidol.
Pantoprazole Pantoprazole The serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.
Temozolomide Temozolomide Haloperidol may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon Zaleplon The risk or severity of CNS depression can be increased when Haloperidol is combined with Zaleplon.
Anakinra Anakinra The metabolism of Haloperidol can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Desloratadine.
Linezolid Linezolid The risk or severity of CNS depression can be increased when Linezolid is combined with Haloperidol.
Trimipramine Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Haloperidol.
Etanercept Injection Etanercept Injection The metabolism of Haloperidol can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Haloperidol can be increased when combined with Armodafinil.
Perindopril Perindopril Haloperidol may decrease the excretion rate of Perindopril which could result in a higher serum level.
Tenofovir Tenofovir The serum concentration of Haloperidol can be increased when it is combined with Tenofovir.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The therapeutic efficacy of Haloperidol can be increased when used in combination with Choline magnesium trisalicylate.
Sirolimus Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Haloperidol.
Dutasteride Dutasteride The metabolism of Dutasteride can be decreased when combined with Haloperidol.
Epinephrine Injection Epinephrine Injection The serum concentration of Haloperidol can be increased when it is combined with Epinephrine.
Eplerenone Eplerenone The metabolism of Eplerenone can be decreased when combined with Haloperidol.
Escitalopram Escitalopram The serum concentration of Escitalopram can be increased when it is combined with Haloperidol.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Haloperidol can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Atomoxetine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of CNS depression can be increased when Haloperidol is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Haloperidol.
Almotriptan Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Haloperidol.
Eletriptan Eletriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Eletriptan.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Haloperidol.
Rosuvastatin Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Haloperidol.
Vardenafil Vardenafil The metabolism of Vardenafil can be decreased when combined with Haloperidol.
Alfuzosin Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Haloperidol.
Aprepitant Aprepitant The serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
Emtricitabine Emtricitabine Haloperidol may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.
Memantine Memantine The risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine.
Tegaserod Tegaserod The serum concentration of Haloperidol can be increased when it is combined with Tegaserod.
Tadalafil Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Haloperidol.
Fosamprenavir Fosamprenavir The serum concentration of Haloperidol can be increased when it is combined with Fosamprenavir.
Frovatriptan Frovatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Gemifloxacin.
Progesterone Progesterone The serum concentration of Haloperidol can be increased when it is combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol.
Infliximab Injection Infliximab Injection The metabolism of Haloperidol can be increased when combined with Infliximab.
Oxandrolone Oxandrolone The metabolism of Haloperidol can be decreased when combined with Oxandrolone.
Protriptyline Protriptyline The serum concentration of Haloperidol can be increased when it is combined with Protriptyline.
Rifaximin Rifaximin The serum concentration of Haloperidol can be increased when it is combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of CNS depression can be increased when Duloxetine is combined with Haloperidol.
Norethindrone Norethindrone The serum concentration of Norethisterone can be increased when it is combined with Haloperidol.
Tinidazole Tinidazole The serum concentration of Tinidazole can be increased when it is combined with Haloperidol.
Trospium Trospium The serum concentration of Trospium can be increased when it is combined with Haloperidol.
Bosentan Bosentan The serum concentration of Haloperidol can be increased when it is combined with Bosentan.
Cefditoren Cefditoren Haloperidol may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet Cinacalcet The serum concentration of Haloperidol can be increased when it is combined with Cinacalcet.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Haloperidol is combined with Eszopiclone.
Ganciclovir Ganciclovir Haloperidol may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Haloperidol.
Ribavirin Ribavirin Haloperidol may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Haloperidol.
Valganciclovir Valganciclovir Haloperidol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Haloperidol.
Adefovir Adefovir Adefovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.
Entecavir Entecavir The metabolism of Haloperidol can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Haloperidol.
Sodium Oxybate Sodium Oxybate The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Haloperidol.
Exenatide Injection Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Haloperidol.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.
Isocarboxazid Isocarboxazid The risk or severity of CNS depression can be increased when Haloperidol is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Ramelteon.
Darifenacin Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Haloperidol.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Haloperidol.
Pregabalin Pregabalin The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The serum concentration of Haloperidol can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine The metabolism of Haloperidol can be increased when combined with Phenylephrine.
Tipranavir Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Haloperidol.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Haloperidol.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Haloperidol.
Ranolazine Ranolazine The metabolism of Ranolazine can be decreased when combined with Haloperidol.
Abatacept Injection Abatacept Injection The metabolism of Haloperidol can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of CNS depression can be increased when Rasagiline is combined with Haloperidol.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Imatinib.
Sitagliptin Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Haloperidol.
Varenicline Varenicline Haloperidol may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib Gefitinib The serum concentration of Haloperidol can be increased when it is combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Haloperidol.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone.
Exemestane Exemestane The serum concentration of Haloperidol can be increased when it is combined with Exemestane.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Haloperidol.
Clofarabine Injection Clofarabine Injection Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Haloperidol.
Lubiprostone Lubiprostone Haloperidol may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Haloperidol.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Haloperidol.
Aliskiren Aliskiren The serum concentration of Haloperidol can be increased when it is combined with Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Haloperidol may increase the neurotoxic activities of Bismuth subsalicylate.
Darunavir Darunavir The serum concentration of Darunavir can be increased when it is combined with Haloperidol.
Pemetrexed Injection Pemetrexed Injection Haloperidol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Haloperidol.
Nabilone Nabilone The risk or severity of CNS depression can be increased when Nabilone is combined with Haloperidol.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Haloperidol.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Haloperidol.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Haloperidol.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Haloperidol.
Dronabinol Dronabinol The risk or severity of CNS depression can be increased when Dronabinol is combined with Haloperidol.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Levocetirizine.
Pegaptanib Injection Pegaptanib Injection Haloperidol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dasatinib.
Mexiletine Mexiletine The serum concentration of Haloperidol can be increased when it is combined with Mexiletine.
Armodafinil Armodafinil The metabolism of Haloperidol can be increased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Haloperidol may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Ivermectin Ivermectin The serum concentration of Haloperidol can be increased when it is combined with Ivermectin.
Temsirolimus Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.
Maraviroc Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Haloperidol.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Toremifene.
Bexarotene Bexarotene The serum concentration of Haloperidol can be increased when it is combined with Bexarotene.
Budesonide Budesonide The serum concentration of Haloperidol can be increased when it is combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The serum concentration of Haloperidol can be increased when it is combined with Chloramphenicol.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Haloperidol.
Doripenem Injection Doripenem Injection Haloperidol may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine Etravirine The serum concentration of Haloperidol can be increased when it is combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The serum concentration of Haloperidol can be increased when it is combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of CNS depression can be increased when Haloperidol is combined with Desvenlafaxine.
Cevimeline Cevimeline The serum concentration of Cevimeline can be increased when it is combined with Haloperidol.
Nebivolol Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
Tretinoin Tretinoin The serum concentration of Tretinoin can be increased when it is combined with Haloperidol.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Haloperidol.
Pilocarpine Pilocarpine The serum concentration of Haloperidol can be increased when it is combined with Pilocarpine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Flecainide.
Certolizumab Injection Certolizumab Injection The metabolism of Haloperidol can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The serum concentration of Ixabepilone can be increased when it is combined with Haloperidol.
Irinotecan Injection Irinotecan Injection The serum concentration of Irinotecan can be increased when it is combined with Haloperidol.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Estramustine Estramustine The serum concentration of Haloperidol can be increased when it is combined with Estramustine.
Praziquantel Praziquantel The serum concentration of Praziquantel can be increased when it is combined with Haloperidol.
Methylnaltrexone Injection Methylnaltrexone Injection Haloperidol may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The risk or severity of CNS depression can be increased when Rufinamide is combined with Haloperidol.
Silodosin Silodosin The serum concentration of Haloperidol can be increased when it is combined with Silodosin.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Haloperidol.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Eltrombopag Eltrombopag The metabolism of Haloperidol can be decreased when combined with Eltrombopag.
Milnacipran Milnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The serum concentration of Haloperidol can be increased when it is combined with Dexlansoprazole.
Plerixafor Injection Plerixafor Injection Haloperidol may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Haloperidol.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Haloperidol.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Haloperidol.
Prasugrel Prasugrel The serum concentration of Prasugrel can be increased when it is combined with Haloperidol.
Lacosamide Lacosamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Lacosamide.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Haloperidol.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
Pralatrexate Injection Pralatrexate Injection Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Palonosetron.
Saxagliptin Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Haloperidol.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Haloperidol.
Golimumab Injection Golimumab Injection The metabolism of Haloperidol can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of CNS depression can be increased when Haloperidol is combined with Vigabatrin.
Pitavastatin Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Haloperidol.
Albendazole Albendazole The serum concentration of Albendazole can be increased when it is combined with Haloperidol.
Ulipristal Ulipristal The serum concentration of Haloperidol can be increased when it is combined with Ulipristal.
Levonorgestrel Levonorgestrel The serum concentration of Haloperidol can be increased when it is combined with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxymorphone.
Liraglutide Injection Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Haloperidol.
Tocilizumab Injection Tocilizumab Injection The metabolism of Haloperidol can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine The risk or severity of seizure can be increased when Haloperidol is combined with Dalfampridine.
Fingolimod Fingolimod The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Haloperidol.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Lurasidone Lurasidone The metabolism of Lurasidone can be decreased when combined with Haloperidol.
Acetaminophen Injection Acetaminophen Injection The serum concentration of Haloperidol can be increased when it is combined with Acetaminophen.
Vilazodone Vilazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Vilazodone.
Ipilimumab Injection Ipilimumab Injection Haloperidol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection The serum concentration of Haloperidol can be increased when it is combined with Aldesleukin.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol.
Busulfan Injection Busulfan Injection The serum concentration of Busulfan can be increased when it is combined with Haloperidol.
Roflumilast Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Haloperidol.
Linagliptin Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Haloperidol.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Rilpivirine.
Cyclophosphamide Injection Cyclophosphamide Injection The serum concentration of Cyclophosphamide can be increased when it is combined with Haloperidol.
Abiraterone Abiraterone The serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.
Ticagrelor Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Haloperidol can be increased when it is combined with Brentuximab vedotin.
Ruxolitinib Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Haloperidol.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Vandetanib.
Clobazam Clobazam The risk or severity of CNS depression can be increased when Clobazam is combined with Haloperidol.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.
Vismodegib Vismodegib The serum concentration of Haloperidol can be increased when it is combined with Vismodegib.
Ivacaftor Ivacaftor The metabolism of Haloperidol can be decreased when combined with Ivacaftor.
Deferiprone Deferiprone Haloperidol may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The serum concentration of Axitinib can be increased when it is combined with Haloperidol.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Haloperidol.
Cabergoline Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Haloperidol.
Naloxone Injection Naloxone Injection The serum concentration of Naloxone can be increased when it is combined with Haloperidol.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Haloperidol.
Fondaparinux Injection Fondaparinux Injection Haloperidol may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine Ezogabine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tiagabine.
Enzalutamide Enzalutamide The serum concentration of Haloperidol can be increased when it is combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mirabegron.
Regorafenib Regorafenib The serum concentration of Haloperidol can be increased when it is combined with Regorafenib.
Bosutinib Bosutinib The serum concentration of Haloperidol can be increased when it is combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The serum concentration of Haloperidol can be increased when it is combined with Corticotropin.
Teriflunomide Teriflunomide The serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.
Lorcaserin Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Haloperidol.
Cabozantinib (thyroid cancer) Cabozantinib (thyroid cancer) The serum concentration of Cabozantinib can be increased when it is combined with Haloperidol.
Teduglutide Injection Teduglutide Injection Haloperidol may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Bedaquiline.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Haloperidol.
Alogliptin Alogliptin The serum concentration of Alogliptin can be increased when it is combined with Haloperidol.
Ponatinib Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Haloperidol.
Pomalidomide Pomalidomide The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Haloperidol.
Apixaban Apixaban The serum concentration of Apixaban can be increased when it is combined with Haloperidol.
Canagliflozin Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol.
Ospemifene Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Haloperidol.
Trametinib Trametinib Haloperidol may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Vortioxetine Vortioxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Vortioxetine.
Perampanel Perampanel The risk or severity of CNS depression can be increased when Perampanel is combined with Haloperidol.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Haloperidol.
Lomitapide Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Haloperidol.
Avanafil Avanafil The metabolism of Avanafil can be decreased when combined with Haloperidol.
Ketorolac Injection Ketorolac Injection The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketorolac.
Simeprevir Simeprevir The serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
Sofosbuvir Sofosbuvir Haloperidol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin The serum concentration of Haloperidol can be increased when it is combined with Dapagliflozin.
Apremilast Apremilast The serum concentration of Haloperidol can be increased when it is combined with Apremilast.
Droxidopa Droxidopa Haloperidol may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol.
Siltuximab Injection Siltuximab Injection The serum concentration of Haloperidol can be increased when it is combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Haloperidol.
Eslicarbazepine Eslicarbazepine The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine.
Belinostat Injection Belinostat Injection The metabolism of Haloperidol can be increased when combined with Belinostat.
Idelalisib Idelalisib The serum concentration of Haloperidol can be increased when it is combined with Idelalisib.
Testosterone Injection Testosterone Injection The serum concentration of Testosterone can be increased when it is combined with Haloperidol.
Oritavancin Injection Oritavancin Injection The serum concentration of Haloperidol can be increased when it is combined with Oritavancin.
Empagliflozin Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.
Vorapaxar Vorapaxar The serum concentration of Haloperidol can be increased when it is combined with Vorapaxar.
Hydrocodone Hydrocodone Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Haloperidol.
Edoxaban Edoxaban Haloperidol may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon beta-1a.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Haloperidol.
Methamphetamine Methamphetamine The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Haloperidol.
Tasimelteon Tasimelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Tasimelteon.
Riociguat Riociguat The serum concentration of Haloperidol can be increased when it is combined with Riociguat.
Lanreotide Injection Lanreotide Injection The serum concentration of Haloperidol can be increased when it is combined with Lanreotide.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Haloperidol.
Nintedanib Nintedanib The serum concentration of Haloperidol can be increased when it is combined with Nintedanib.
Secukinumab Injection Secukinumab Injection The metabolism of Haloperidol can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Risperidone.
Palbociclib Palbociclib The serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Haloperidol.
Naloxegol Naloxegol The metabolism of Naloxegol can be decreased when combined with Haloperidol.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Panobinostat.
Ivabradine Ivabradine The metabolism of Ivabradine can be decreased when combined with Haloperidol.
Amiloride Amiloride Amiloride may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Haloperidol can be increased when it is combined with Isavuconazonium.
Macitentan Macitentan The serum concentration of Macitentan can be increased when it is combined with Haloperidol.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Haloperidol.
Flibanserin Flibanserin The metabolism of Haloperidol can be decreased when combined with Flibanserin.
Rolapitant Rolapitant The serum concentration of Rolapitant can be increased when it is combined with Haloperidol.
Prednisolone Prednisolone The serum concentration of Haloperidol can be increased when it is combined with Prednisolone.
Daclatasvir Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Haloperidol.
Brexpiprazole Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Haloperidol.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Haloperidol.
Cariprazine Cariprazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Haloperidol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Haloperidol.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Haloperidol.
Trabectedin Injection Trabectedin Injection The serum concentration of Trabectedin can be increased when it is combined with Haloperidol.
Osimertinib Osimertinib The serum concentration of Haloperidol can be increased when it is combined with Osimertinib.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Haloperidol.
Ixazomib Ixazomib The serum concentration of Ixazomib can be increased when it is combined with Haloperidol.
Rifapentine Rifapentine The serum concentration of Haloperidol can be increased when it is combined with Rifapentine.
Lesinurad Lesinurad Haloperidol may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The serum concentration of Haloperidol can be increased when it is combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brivaracetam.
Venetoclax Venetoclax The serum concentration of Haloperidol can be increased when it is combined with Venetoclax.
Cobicistat Cobicistat The serum concentration of Haloperidol can be increased when it is combined with Cobicistat.
Selexipag Selexipag The serum concentration of Haloperidol can be increased when it is combined with Selexipag.
Pimavanserin Pimavanserin The risk or severity of CNS depression can be increased when Haloperidol is combined with Pimavanserin.
Obeticholic Acid Obeticholic Acid The metabolism of Haloperidol can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Haloperidol may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Haloperidol.
Lixisenatide Injection Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Haloperidol.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ribociclib.
Brigatinib Brigatinib The serum concentration of Haloperidol can be increased when it is combined with Brigatinib.
Doxepin (Insomnia) Doxepin (Insomnia) The serum concentration of Doxepin can be increased when it is combined with Haloperidol.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Deutetrabenazine.
Valbenazine Valbenazine The serum concentration of Valbenazine can be increased when it is combined with Haloperidol.
Deflazacort Deflazacort The serum concentration of Haloperidol can be increased when it is combined with Deflazacort.
Safinamide Safinamide The risk or severity of CNS depression can be increased when Safinamide is combined with Haloperidol.
Naldemedine Naldemedine Haloperidol may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Sarilumab Injection Sarilumab Injection The serum concentration of Haloperidol can be increased when it is combined with Sarilumab.
Midostaurin Midostaurin The serum concentration of Haloperidol can be increased when it is combined with Midostaurin.
Neratinib Neratinib The serum concentration of Haloperidol can be increased when it is combined with Neratinib.
Enasidenib Enasidenib The serum concentration of Haloperidol can be increased when it is combined with Enasidenib.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The serum concentration of Fosaprepitant can be increased when it is combined with Haloperidol.
Benznidazole Benznidazole Haloperidol may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Haloperidol.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Haloperidol.
Abemaciclib Abemaciclib The serum concentration of Haloperidol can be increased when it is combined with Abemaciclib.
Acalabrutinib Acalabrutinib The serum concentration of Haloperidol can be increased when it is combined with Acalabrutinib.
Letermovir Letermovir The serum concentration of Letermovir can be increased when it is combined with Haloperidol.
Semaglutide Injection Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Haloperidol.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Haloperidol.
Buprenorphine Injection Buprenorphine Injection Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Haloperidol can be increased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The serum concentration of Haloperidol can be increased when it is combined with Fostamatinib.
Avatrombopag Avatrombopag The metabolism of Haloperidol can be increased when combined with Avatrombopag.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Haloperidol.
Lofexidine Lofexidine The therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine.
Plazomicin Injection Plazomicin Injection Haloperidol may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Haloperidol.
Encorafenib Encorafenib The serum concentration of Encorafenib can be increased when it is combined with Haloperidol.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Haloperidol.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol.
Elagolix Elagolix The serum concentration of Elagolix can be increased when it is combined with Haloperidol.
Eravacycline Injection Eravacycline Injection The serum concentration of Haloperidol can be increased when it is combined with Eravacycline.
Doravirine Doravirine The serum concentration of Doravirine can be increased when it is combined with Haloperidol.
Tafenoquine Tafenoquine The serum concentration of Tafenoquine can be increased when it is combined with Haloperidol.
Cannabidiol Cannabidiol The risk or severity of CNS depression can be increased when Cannabidiol is combined with Haloperidol.
Dacomitinib Dacomitinib The serum concentration of Haloperidol can be increased when it is combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Haloperidol can be increased when it is combined with Duvelisib.
Stiripentol Stiripentol The risk or severity of CNS depression can be increased when Stiripentol is combined with Haloperidol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Haloperidol.
Larotrectinib Larotrectinib The serum concentration of Haloperidol can be increased when it is combined with Larotrectinib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The serum concentration of Paclitaxel can be increased when it is combined with Haloperidol.
Rifamycin Rifamycin The serum concentration of Haloperidol can be increased when it is combined with Rifamycin.
Prucalopride Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Haloperidol.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Haloperidol can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Haloperidol is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Erdafitinib Erdafitinib The serum concentration of Erdafitinib can be increased when it is combined with Haloperidol.
Esomeprazole Injection Esomeprazole Injection The serum concentration of Haloperidol can be increased when it is combined with Esomeprazole.
Alpelisib Alpelisib The serum concentration of Haloperidol can be increased when it is combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brexanolone.
Polatuzumab vedotin-piiq Injection Polatuzumab vedotin-piiq Injection The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin.
Solriamfetol Solriamfetol The risk or severity of CNS depression can be increased when Haloperidol is combined with Solriamfetol.
Selinexor Selinexor The serum concentration of Haloperidol can be increased when it is combined with Selinexor.
Darolutamide Darolutamide The serum concentration of Haloperidol can be increased when it is combined with Darolutamide.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Haloperidol.
Entrectinib Entrectinib The metabolism of Entrectinib can be decreased when combined with Haloperidol.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Haloperidol.
Upadacitinib Upadacitinib The serum concentration of Haloperidol can be increased when it is combined with Upadacitinib.
Istradefylline Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Haloperidol.
Pitolisant Pitolisant The serum concentration of Haloperidol can be decreased when it is combined with Pitolisant.
Pretomanid Pretomanid The serum concentration of Pretomanid can be increased when it is combined with Haloperidol.
Fedratinib Fedratinib The serum concentration of Haloperidol can be increased when it is combined with Fedratinib.
Lefamulin Lefamulin Haloperidol may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection Phenytoin Injection The risk or severity of CNS depression can be increased when Phenytoin is combined with Haloperidol.
Fosphenytoin Injection Fosphenytoin Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Haloperidol.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Haloperidol.
Avapritinib Avapritinib The serum concentration of Avapritinib can be increased when it is combined with Haloperidol.
Lumateperone Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Haloperidol.
Lasmiditan Lasmiditan The risk or severity of CNS depression can be increased when Haloperidol is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Haloperidol.
Tazemetostat Tazemetostat The serum concentration of Haloperidol can be increased when it is combined with Tazemetostat.
Cenobamate Cenobamate The serum concentration of Haloperidol can be decreased when it is combined with Cenobamate.
Pemigatinib Pemigatinib The metabolism of Pemigatinib can be decreased when combined with Haloperidol.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Haloperidol.
Rimegepant Rimegepant The metabolism of Rimegepant can be decreased when combined with Haloperidol.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Haloperidol.
Remdesivir Injection Remdesivir Injection The serum concentration of Haloperidol can be increased when it is combined with Remdesivir.
Ripretinib Ripretinib The serum concentration of Haloperidol can be increased when it is combined with Ripretinib.
Selpercatinib Selpercatinib The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Haloperidol.
Capmatinib Capmatinib The serum concentration of Haloperidol can be increased when it is combined with Capmatinib.
Lemborexant Lemborexant The risk or severity of CNS depression can be increased when Haloperidol is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of CNS depression can be increased when Fenfluramine is combined with Haloperidol.
Fostemsavir Fostemsavir The serum concentration of Haloperidol can be increased when it is combined with Fostemsavir.
Lurbinectedin Injection Lurbinectedin Injection The serum concentration of Lurbinectedin can be increased when it is combined with Haloperidol.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.
Pralsetinib Pralsetinib The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib.
Opicapone Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Haloperidol.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Haloperidol can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection Haloperidol may increase the neurotoxic activities of Naxitamab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Haloperidol.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The serum concentration of Haloperidol can be increased when it is combined with Drospirenone.
Viloxazine Viloxazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol) Vitamin E (Alpha-Tocopherol) The serum concentration of Haloperidol can be increased when it is combined with Vitamin E.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Theophylline Theophylline The serum concentration of Theophylline can be increased when it is combined with Haloperidol.
Fenoprofen Fenoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Fenoprofen.
Indomethacin Indomethacin The therapeutic efficacy of Haloperidol can be increased when used in combination with Indomethacin.
Mefenamic Acid Mefenamic Acid The therapeutic efficacy of Haloperidol can be increased when used in combination with Mefenamic acid.
Naproxen Naproxen The therapeutic efficacy of Haloperidol can be increased when used in combination with Naproxen.
Tolmetin Tolmetin The therapeutic efficacy of Haloperidol can be increased when used in combination with Tolmetin.
Sulindac Sulindac The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulindac.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Haloperidol.
Isotretinoin Isotretinoin The serum concentration of Isotretinoin can be increased when it is combined with Haloperidol.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Hydroxyurea Hydroxyurea The serum concentration of Haloperidol can be increased when it is combined with Hydroxyurea.
Floxuridine Floxuridine The metabolism of Haloperidol can be decreased when combined with Floxuridine.
Phenobarbital Phenobarbital The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenobarbital.
Metaxalone Metaxalone The risk or severity of CNS depression can be increased when Haloperidol is combined with Metaxalone.
Methotrexate Injection Methotrexate Injection The serum concentration of Haloperidol can be increased when it is combined with Methotrexate.
Levorphanol Levorphanol The risk or severity of CNS depression can be increased when Haloperidol is combined with Levorphanol.
Primidone Primidone The risk or severity of CNS depression can be increased when Haloperidol is combined with Primidone.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Methsuximide.
Diethylpropion Diethylpropion The therapeutic efficacy of Diethylpropion can be decreased when used in combination with Haloperidol.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Haloperidol.
Diazepam Diazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of CNS depression can be increased when Haloperidol is combined with Clorazepic acid.
Lorazepam Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Haloperidol.
Carmustine Carmustine The metabolism of Haloperidol can be decreased when combined with Carmustine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Haloperidol.
Codeine Codeine The risk or severity of CNS depression can be increased when Haloperidol is combined with Codeine.
Meprobamate Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Haloperidol.
Chlordiazepoxide Chlordiazepoxide The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Haloperidol.
Bromocriptine Bromocriptine The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tranylcypromine.
Phenelzine Phenelzine The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of CNS depression can be increased when Procarbazine is combined with Haloperidol.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of CNS depression can be increased when Ergoloid mesylate is combined with Haloperidol.
Tetracycline Tetracycline The serum concentration of Tetracycline can be increased when it is combined with Haloperidol.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Haloperidol.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluoperazine.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dapsone Dapsone The serum concentration of Haloperidol can be increased when it is combined with Dapsone.
Sulfadiazine Sulfadiazine The serum concentration of Sulfadiazine can be increased when it is combined with Haloperidol.
Oxycodone Oxycodone The risk or severity of CNS depression can be increased when Oxycodone is combined with Haloperidol.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
Oxybutynin Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Haloperidol.
Benztropine Benztropine The risk or severity of adverse effects can be increased when Haloperidol is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Maprotiline.
Ibuprofen Ibuprofen The serum concentration of Haloperidol can be increased when it is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Haloperidol.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Orphenadrine.
Perphenazine Perphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Haloperidol.
Fluphenazine Fluphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Fluphenazine.
Phentermine Phentermine The therapeutic efficacy of Phentermine can be decreased when used in combination with Haloperidol.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
Amoxapine Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Haloperidol.
Sulfasalazine Sulfasalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulfasalazine.
Hydrocortisone Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Haloperidol.
Doxorubicin Doxorubicin The serum concentration of Haloperidol can be increased when it is combined with Doxorubicin.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Carbamazepine can be increased when combined with Haloperidol.
Molindone Molindone The risk or severity of CNS depression can be increased when Haloperidol is combined with Molindone.
Methyldopa Methyldopa Haloperidol may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Haloperidol.
Hydralazine Hydralazine The serum concentration of Hydralazine can be increased when it is combined with Haloperidol.
Cimetidine Cimetidine The serum concentration of Haloperidol can be increased when it is combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Warfarin Warfarin The serum concentration of Warfarin can be increased when it is combined with Haloperidol.
Clonazepam Clonazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Clonazepam.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Loperamide.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Haloperidol.
Meclofenamate Meclofenamate The therapeutic efficacy of Haloperidol can be increased when used in combination with Meclofenamic acid.
Daunorubicin Daunorubicin The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.
Nitrofurantoin Nitrofurantoin Haloperidol may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin Griseofulvin The metabolism of Haloperidol can be increased when combined with Griseofulvin.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Haloperidol.
Loxapine Loxapine The risk or severity of CNS depression can be increased when Loxapine is combined with Haloperidol.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Haloperidol.
Calcitriol Calcitriol The serum concentration of Haloperidol can be increased when it is combined with Calcitriol.
Triamterene Triamterene The metabolism of Haloperidol can be decreased when combined with Triamterene.
Sulfinpyrazone Sulfinpyrazone The serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide Chlorothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Chlorthalidone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Haloperidol may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection Clindamycin Injection The serum concentration of Clindamycin can be increased when it is combined with Haloperidol.
Secobarbital Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Haloperidol.
Desipramine Desipramine The serum concentration of Desipramine can be increased when it is combined with Haloperidol.
Amitriptyline Amitriptyline The serum concentration of Haloperidol can be increased when it is combined with Amitriptyline.
Imipramine Imipramine The serum concentration of Haloperidol can be increased when it is combined with Imipramine.
Probenecid Probenecid The metabolism of Probenecid can be decreased when combined with Haloperidol.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Procainamide.
Isoniazid Isoniazid The serum concentration of Isoniazid can be increased when it is combined with Haloperidol.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Rifampin Rifampin The metabolism of Haloperidol can be increased when combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Haloperidol.
Butabarbital Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Haloperidol.
Liothyronine Liothyronine Liothyronine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Methimazole Methimazole The serum concentration of Haloperidol can be increased when it is combined with Methimazole.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Haloperidol.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Haloperidol.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Haloperidol.
Dextromethorphan Dextromethorphan The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Haloperidol.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyclobenzaprine.
Niacin Niacin The serum concentration of Haloperidol can be increased when it is combined with Niacin.
Baclofen Baclofen The risk or severity of CNS depression can be increased when Baclofen is combined with Haloperidol.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol.
Meclizine Meclizine The risk or severity of CNS depression can be increased when Haloperidol is combined with Meclizine.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Haloperidol.
Dantrolene Dantrolene The risk or severity of CNS depression can be increased when Haloperidol is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Haloperidol.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Haloperidol.
Methocarbamol Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Haloperidol.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Danazol Danazol The serum concentration of Haloperidol can be increased when it is combined with Danazol.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Haloperidol.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Propranolol.
Pseudoephedrine Pseudoephedrine The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Haloperidol.
Nortriptyline Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Haloperidol.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B.
Phytonadione Phytonadione Haloperidol may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nadolol Nadolol The serum concentration of Nadolol can be increased when it is combined with Haloperidol.
Butorphanol Injection Butorphanol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Nalbuphine.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.
Trimethobenzamide Trimethobenzamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Trimethobenzamide.
Flavoxate Flavoxate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Fluorouracil.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Haloperidol.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cephalexin Cephalexin The serum concentration of Haloperidol can be increased when it is combined with Cephalexin.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dacarbazine Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Haloperidol.
Acetazolamide Acetazolamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Acetazolamide.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ketoconazole Ketoconazole The metabolism of Haloperidol can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of CNS depression can be increased when Haloperidol is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The serum concentration of Haloperidol can be increased when it is combined with Thiotepa.
Vincristine Injection Vincristine Injection The serum concentration of Vincristine can be increased when it is combined with Haloperidol.
Vinblastine Vinblastine The serum concentration of Haloperidol can be increased when it is combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Metoprolol Metoprolol The serum concentration of Haloperidol can be increased when it is combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Haloperidol.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thiothixene.
Aspirin Aspirin The therapeutic efficacy of Haloperidol can be increased when used in combination with Acetylsalicylic acid.
Salsalate Salsalate The therapeutic efficacy of Haloperidol can be increased when used in combination with Salsalate.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Haloperidol.
Temazepam Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Haloperidol.
Triazolam Triazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Triazolam.
Dicyclomine Dicyclomine Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Haloperidol.
Propantheline Propantheline Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim The serum concentration of Haloperidol can be increased when it is combined with Trimethoprim.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Haloperidol.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Haloperidol.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Haloperidol.
Verapamil Verapamil The serum concentration of Haloperidol can be increased when it is combined with Verapamil.
Atenolol Atenolol The serum concentration of Atenolol can be increased when it is combined with Haloperidol.
Pindolol Pindolol The risk or severity of CNS depression can be increased when Haloperidol is combined with Pindolol.
Cisplatin Injection Cisplatin Injection Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal The therapeutic efficacy of Haloperidol can be increased when used in combination with Diflunisal.
Piroxicam Piroxicam The therapeutic efficacy of Haloperidol can be increased when used in combination with Piroxicam.
Bumetanide Bumetanide Haloperidol may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Streptozocin Streptozocin The metabolism of Haloperidol can be increased when combined with Streptozocin.
Etoposide Etoposide The serum concentration of Etoposide can be increased when it is combined with Haloperidol.
Glyburide Glyburide The serum concentration of Haloperidol can be increased when it is combined with Glyburide.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Haloperidol.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Haloperidol.
Amoxicillin Amoxicillin Haloperidol may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection Nafcillin Injection The metabolism of Haloperidol can be increased when combined with Nafcillin.
Oxacillin Injection Oxacillin Injection Haloperidol may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Haloperidol.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Labetalol Labetalol The serum concentration of Haloperidol can be increased when it is combined with Labetalol.
Auranofin Auranofin Haloperidol may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.
Gemfibrozil Gemfibrozil The serum concentration of Haloperidol can be increased when it is combined with Gemfibrozil.
Guanabenz Guanabenz The metabolism of Guanabenz can be decreased when combined with Haloperidol.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ketoprofen Ketoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketoprofen.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pimozide.
Flurbiprofen Flurbiprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Buspirone Buspirone The serum concentration of Buspirone can be increased when it is combined with Haloperidol.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Haloperidol.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Haloperidol.
Mesalamine Mesalamine The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine.
Diclofenac Diclofenac The serum concentration of Haloperidol can be increased when it is combined with Diclofenac.
Fluoxetine Fluoxetine The metabolism of Haloperidol can be decreased when combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Haloperidol.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Haloperidol.
Estazolam Estazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Estazolam.
Idarubicin Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Haloperidol.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ofloxacin.
Didanosine Didanosine Haloperidol may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Haloperidol may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Haloperidol.
Etodolac Etodolac The therapeutic efficacy of Haloperidol can be increased when used in combination with Etodolac.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Felodipine.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nabumetone Nabumetone The therapeutic efficacy of Haloperidol can be increased when used in combination with Nabumetone.
Simvastatin Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Haloperidol.
Amlodipine Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Haloperidol.
Teniposide Injection Teniposide Injection The serum concentration of Haloperidol can be increased when it is combined with Teniposide.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Haloperidol.
Lisinopril Lisinopril Haloperidol may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin Oxaprozin The therapeutic efficacy of Haloperidol can be increased when used in combination with Oxaprozin.
Atovaquone Atovaquone The serum concentration of Haloperidol can be increased when it is combined with Atovaquone.
Rifabutin Rifabutin The serum concentration of Haloperidol can be increased when it is combined with Rifabutin.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sotalol.
Bisoprolol Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Haloperidol.
Zolpidem Zolpidem Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The serum concentration of Doxazosin can be increased when it is combined with Haloperidol.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Haloperidol.
Omeprazole Omeprazole The serum concentration of Haloperidol can be increased when it is combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin.
Fluvastatin Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Haloperidol.
Venlafaxine Venlafaxine The serum concentration of Haloperidol can be increased when it is combined with Venlafaxine.
Stavudine Stavudine Haloperidol may increase the neurotoxic activities of Stavudine.
Famciclovir Famciclovir The serum concentration of Famciclovir can be increased when it is combined with Haloperidol.
Fluvoxamine Fluvoxamine The risk or severity of CNS depression can be increased when Fluvoxamine is combined with Haloperidol.
Nefazodone Nefazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Tramadol Tramadol The metabolism of Haloperidol can be decreased when combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Haloperidol.
Lansoprazole Lansoprazole The serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The serum concentration of Ifosfamide can be increased when it is combined with Haloperidol.
Nicardipine Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Haloperidol.
Bupropion Bupropion The risk or severity of seizure can be increased when Haloperidol is combined with Bupropion.
Ticlopidine Ticlopidine The serum concentration of Haloperidol can be increased when it is combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Saquinavir.
Metformin Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.
Nisoldipine Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Haloperidol.
Lamivudine Lamivudine Haloperidol may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Riluzole Riluzole The risk or severity of CNS depression can be increased when Haloperidol is combined with Riluzole.
Acarbose Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Haloperidol.
Glimepiride Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Haloperidol.
Gemcitabine Injection Gemcitabine Injection Gemcitabine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Indinavir Indinavir The serum concentration of Indinavir can be increased when it is combined with Haloperidol.
Ritonavir Ritonavir The serum concentration of Haloperidol can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The serum concentration of Docetaxel can be increased when it is combined with Haloperidol.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Meropenem Injection Meropenem Injection Haloperidol may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Haloperidol.
Zafirlukast Zafirlukast The serum concentration of Haloperidol can be increased when it is combined with Zafirlukast.
Fosfomycin Fosfomycin Haloperidol may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Haloperidol.
Topiramate Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Haloperidol.
Zileuton Zileuton The serum concentration of Zileuton can be increased when it is combined with Haloperidol.
Valsartan Valsartan The metabolism of Haloperidol can be decreased when combined with Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Haloperidol.
Pramipexole Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Haloperidol.
Donepezil Donepezil The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Haloperidol.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Haloperidol.
Loratadine Loratadine The risk or severity of QTc prolongation can be increased when Loratadine is combined with Haloperidol.
Carvedilol Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Haloperidol.
Nilutamide Nilutamide The metabolism of Haloperidol can be decreased when combined with Nilutamide.
Flutamide Flutamide The serum concentration of Haloperidol can be increased when it is combined with Flutamide.
Selegiline Selegiline The risk or severity of CNS depression can be increased when Haloperidol is combined with Selegiline.
Bicalutamide Bicalutamide The serum concentration of Haloperidol can be increased when it is combined with Bicalutamide.
Sertraline Sertraline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sertraline.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Haloperidol.
Letrozole Letrozole The serum concentration of Haloperidol can be increased when it is combined with Letrozole.
Raloxifene Raloxifene The serum concentration of Haloperidol can be increased when it is combined with Raloxifene.
Irbesartan Irbesartan The serum concentration of Irbesartan can be increased when it is combined with Haloperidol.
Tamsulosin Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Haloperidol.
Ropinirole Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Haloperidol.
Finasteride Finasteride The serum concentration of Finasteride can be increased when it is combined with Haloperidol.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Haloperidol.
Paroxetine Paroxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Haloperidol.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Haloperidol.
Capecitabine Capecitabine The metabolism of Haloperidol can be decreased when combined with Capecitabine.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Haloperidol.
Abacavir Abacavir Haloperidol may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil Sildenafil The serum concentration of Haloperidol can be increased when it is combined with Sildenafil.
Pioglitazone Pioglitazone The serum concentration of Pioglitazone can be increased when it is combined with Haloperidol.
Celecoxib Celecoxib The serum concentration of Haloperidol can be increased when it is combined with Celecoxib.
Rosiglitazone Rosiglitazone The serum concentration of Rosiglitazone can be increased when it is combined with Haloperidol.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Haloperidol.
Thalidomide Thalidomide Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Balsalazide Balsalazide The therapeutic efficacy of Haloperidol can be increased when used in combination with Balsalazide.
Nateglinide Nateglinide The serum concentration of Nateglinide can be increased when it is combined with Haloperidol.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Haloperidol.
Levetiracetam Levetiracetam The risk or severity of CNS depression can be increased when Haloperidol is combined with Levetiracetam.
Rabeprazole Rabeprazole The serum concentration of Rabeprazole can be increased when it is combined with Haloperidol.
Terbinafine Terbinafine The serum concentration of Haloperidol can be increased when it is combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists